{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T12:28:30Z","timestamp":1759667310319,"version":"3.37.3"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,1,23]],"date-time":"2016-01-23T00:00:00Z","timestamp":1453507200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["SFRH\/BD\/98536\/2013"],"award-info":[{"award-number":["SFRH\/BD\/98536\/2013"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Minist\u00e9rio da Sa\u00fade (PT)","award":["CFICS-45\/2007"],"award-info":[{"award-number":["CFICS-45\/2007"]}]},{"name":"Instituto Portugu\u00eas de Oncologia do Porto-Centro de Investiga\u00e7\u00e3o","award":["CI-IPOP-22-2015"],"award-info":[{"award-number":["CI-IPOP-22-2015"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s00228-016-2015-3","type":"journal-article","created":{"date-parts":[[2016,1,23]],"date-time":"2016-01-23T01:20:19Z","timestamp":1453512019000},"page":"545-553","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Improvement of a predictive model in ovarian cancer patients submitted to platinum-based chemotherapy: implications of a GST activity profile"],"prefix":"10.1007","volume":"72","author":[{"given":"Deolinda","family":"Pereira","sequence":"first","affiliation":[]},{"given":"Joana","family":"Assis","sequence":"additional","affiliation":[]},{"given":"M\u00f3nica","family":"Gomes","sequence":"additional","affiliation":[]},{"given":"Augusto","family":"Nogueira","sequence":"additional","affiliation":[]},{"given":"Rui","family":"Medeiros","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2016,1,23]]},"reference":[{"issue":"5","key":"2015_CR1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","volume":"136","author":"J Ferlay","year":"2015","unstructured":"Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359\u2013E386. doi: 10.1002\/ijc.29210","journal-title":"Int J Cancer"},{"key":"2015_CR2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1146\/annurev.pathol.4.110807.092246","volume":"4","author":"KR Cho","year":"2009","unstructured":"Cho KR, Shih Ie M (2009) Ovarian cancer. Annu Rev Pathol 4:287\u2013313. doi: 10.1146\/annurev.pathol.4.110807.092246","journal-title":"Annu Rev Pathol"},{"issue":"4","key":"2015_CR3","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3322\/caac.20006","volume":"59","author":"A Jemal","year":"2009","unstructured":"Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59(4):225\u2013249. doi: 10.3322\/caac.20006","journal-title":"CA Cancer J Clin"},{"issue":"4","key":"2015_CR4","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1210\/en.2011-2123","volume":"153","author":"I Romero","year":"2012","unstructured":"Romero I, Bast RC Jr (2012) Minireview: human ovarian cancer: biology, current management, and paths to personalizing therapy. Endocrinology 153(4):1593\u20131602. doi: 10.1210\/en.2011-2123","journal-title":"Endocrinology"},{"key":"2015_CR5","unstructured":"National Comprehensive Cancer Network. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer (version 2.2015). Accessed 11 September 2015"},{"issue":"6","key":"2015_CR6","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1097\/01.AOG.0000220516.34053.48","volume":"107","author":"S Bhoola","year":"2006","unstructured":"Bhoola S, Hoskins WJ (2006) Diagnosis and management of epithelial ovarian cancer. Obstet Gynecol 107(6):1399\u20131410. doi: 10.1097\/01.AOG.0000220516.34053.48","journal-title":"Obstet Gynecol"},{"issue":"10 Suppl","key":"2015_CR7","doi-asserted-by":"crossref","first-page":"149s","DOI":"10.1200\/JCO.2003.02.553","volume":"21","author":"MA Bookman","year":"2003","unstructured":"Bookman MA (2003) Developmental chemotherapy and management of recurrent ovarian cancer. J Clin Oncol 21(10 Suppl):149s\u2013167s","journal-title":"J Clin Oncol"},{"key":"2015_CR8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s40360-015-0001-5","volume":"16","author":"S Lambrechts","year":"2015","unstructured":"Lambrechts S, Lambrechts D, Despierre E, Van Nieuwenhuysen E, Smeets D, Debruyne PR, Renard V, Vroman P, Luyten D, Neven P, Amant F, Leunen K, Vergote I (2015) Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer. BMC Pharmacol Toxicol 16:2. doi: 10.1186\/s40360-015-0001-5","journal-title":"BMC Pharmacol Toxicol"},{"issue":"2","key":"2015_CR9","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.ygyno.2011.10.034","volume":"124","author":"I Diaz-Padilla","year":"2012","unstructured":"Diaz-Padilla I, Amir E, Marsh S, Liu G, Mackay H (2012) Genetic polymorphisms as predictive and prognostic biomarkers in gynecological cancers: a systematic review. Gynecol Oncol 124(2):354\u2013365. doi: 10.1016\/j.ygyno.2011.10.034","journal-title":"Gynecol Oncol"},{"issue":"5","key":"2015_CR10","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/tpj.2014.32","volume":"14","author":"E Caiola","year":"2014","unstructured":"Caiola E, Broggini M, Marabese M (2014) Genetic markers for prediction of treatment outcomes in ovarian cancer. Pharmacogenomics J 14(5):401\u2013410. doi: 10.1038\/tpj.2014.32","journal-title":"Pharmacogenomics J"},{"issue":"12","key":"2015_CR11","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.2217\/14622416.9.12.1825","volume":"9","author":"AJ Paige","year":"2008","unstructured":"Paige AJ, Brown R (2008) Pharmaco(epi)genomics in ovarian cancer. Pharmacogenomics 9(12):1825\u20131834. doi: 10.2217\/14622416.9.12.1825","journal-title":"Pharmacogenomics"},{"issue":"7","key":"2015_CR12","first-page":"552","volume":"6","author":"J Assis","year":"2013","unstructured":"Assis J, Pereira D, Gomes M, Marques D, Marques I, Nogueira A, Catarino R, Medeiros R (2013) Influence of CYP3A4 genotypes in the outcome of serous ovarian cancer patients treated with first-line chemotherapy: implication of a CYP3A4 activity profile. Int J Clin Exp Med 6(7):552\u2013561","journal-title":"Int J Clin Exp Med"},{"issue":"4","key":"2015_CR13","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.bbrc.2005.08.012","volume":"335","author":"D Pinto","year":"2005","unstructured":"Pinto D, Pereira D, Portela C, da Silva JL, Lopes C, Medeiros R (2005) The influence of HER2 genotypes as molecular markers in ovarian cancer outcome. Biochem Biophys Res Commun 335(4):1173\u20131178. doi: 10.1016\/j.bbrc.2005.08.012","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"2015_CR14","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.bbrc.2005.11.176","volume":"340","author":"AM Santos","year":"2006","unstructured":"Santos AM, Sousa H, Portela C, Pereira D, Pinto D, Catarino R, Rodrigues C, Araujo AP, Lopes C, Medeiros R (2006) TP53 and P21 polymorphisms: response to cisplatinum\/paclitaxel-based chemotherapy in ovarian cancer. Biochem Biophys Res Commun 340(1):256\u2013262. doi: 10.1016\/j.bbrc.2005.11.176","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"2015_CR15","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1007\/s10147-003-0318-8","volume":"8","author":"R Medeiros","year":"2003","unstructured":"Medeiros R, Pereira D, Afonso N, Palmeira C, Faleiro C, Afonso-Lopes C, Freitas-Silva M, Vasconcelos A, Costa S, Osorio T, Lopes C (2003) Platinum\/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome. Int J Clin Oncol 8(3):156\u2013161. doi: 10.1007\/s10147-003-0318-8","journal-title":"Int J Clin Oncol"},{"issue":"7","key":"2015_CR16","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00228-011-1007-6","volume":"67","author":"TK Bergmann","year":"2011","unstructured":"Bergmann TK, Green H, Brasch-Andersen C, Mirza MR, Herrstedt J, Holund B, du Bois A, Damkier P, Vach W, Brosen K, Peterson C (2011) Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer. Eur J Clin Pharmacol 67(7):693\u2013700. doi: 10.1007\/s00228-011-1007-6","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"2015_CR17","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ygyno.2005.08.035","volume":"100","author":"A Beeghly","year":"2006","unstructured":"Beeghly A, Katsaros D, Chen H, Fracchioli S, Zhang Y, Massobrio M, Risch H, Jones B, Yu H (2006) Glutathione S-transferase polymorphisms and ovarian cancer treatment and survival. Gynecol Oncol 100(2):330\u2013337. doi: 10.1016\/j.ygyno.2005.08.035","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2015_CR18","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2478\/10004-1254-60-2009-1885","volume":"60","author":"N Bozina","year":"2009","unstructured":"Bozina N, Bradamante V, Lovric M (2009) Genetic polymorphism of metabolic enzymes P450 (CYP) as a susceptibility factor for drug response, toxicity, and cancer risk. Arh Hig Rada Toksikol 60(2):217\u2013242. doi: 10.2478\/10004-1254-60-2009-1885","journal-title":"Arh Hig Rada Toksikol"},{"issue":"6","key":"2015_CR19","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMra020021","volume":"348","author":"R Weinshilboum","year":"2003","unstructured":"Weinshilboum R (2003) Inheritance and drug response. N Engl J Med 348(6):529\u2013537. doi: 10.1056\/NEJMra020021","journal-title":"N Engl J Med"},{"key":"2015_CR20","unstructured":"Klaassen CD (2008) The basic science of poisons. Casarett & Doull\u2019s Toxicology 7th edn."},{"key":"2015_CR21","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1146\/annurev.pharmtox.45.120403.095857","volume":"45","author":"JD Hayes","year":"2005","unstructured":"Hayes JD, Flanagan JU, Jowsey IR (2005) Glutathione transferases. Annu Rev Pharmacol Toxicol 45:51\u201388. doi: 10.1146\/annurev.pharmtox.45.120403.095857","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"1","key":"2015_CR22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2006.09.006","volume":"33","author":"CA Rabik","year":"2007","unstructured":"Rabik CA, Dolan ME (2007) Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33(1):9\u201323. doi: 10.1016\/j.ctrv.2006.09.006","journal-title":"Cancer Treat Rev"},{"issue":"7","key":"2015_CR23","doi-asserted-by":"crossref","first-page":"3070","DOI":"10.1073\/pnas.89.7.3070","volume":"89","author":"AK Godwin","year":"1992","unstructured":"Godwin AK, Meister A, O\u2019Dwyer PJ, Huang CS, Hamilton TC, Anderson ME (1992) High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci U S A 89(7):3070\u20133074","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2015_CR24","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1021\/tx960072x","volume":"10","author":"RN Armstrong","year":"1997","unstructured":"Armstrong RN (1997) Structure, catalytic mechanism, and evolution of the glutathione transferases. Chem Res Toxicol 10(1):2\u201318. doi: 10.1021\/tx960072x","journal-title":"Chem Res Toxicol"},{"issue":"7","key":"2015_CR25","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1038\/nrc1123","volume":"3","author":"R Agarwal","year":"2003","unstructured":"Agarwal R, Kaye SB (2003) Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer 3(7):502\u2013516. doi: 10.1038\/nrc1123","journal-title":"Nat Rev Cancer"},{"issue":"3","key":"2015_CR26","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1038\/clpt.2011.126","volume":"90","author":"SW Paugh","year":"2011","unstructured":"Paugh SW, Stocco G, McCorkle JR, Diouf B, Crews KR, Evans WE (2011) Cancer pharmacogenomics. Clin Pharmacol Ther 90(3):461\u2013466. doi: 10.1038\/clpt.2011.126","journal-title":"Clin Pharmacol Ther"},{"issue":"12","key":"2015_CR27","first-page":"1239","volume":"10","author":"S Garte","year":"2001","unstructured":"Garte S, Gaspari L, Alexandrie AK, Ambrosone C, Autrup H, Autrup JL, Baranova H, Bathum L, Benhamou S, Boffetta P, Bouchardy C, Breskvar K, Brockmoller J, Cascorbi I, Clapper ML, Coutelle C, Daly A, Dell\u2019Omo M, Dolzan V, Dresler CM, Fryer A, Haugen A, Hein DW, Hildesheim A, Hirvonen A, Hsieh LL, Ingelman-Sundberg M, Kalina I, Kang D, Kihara M, Kiyohara C, Kremers P, Lazarus P, Le Marchand L, Lechner MC, van Lieshout EM, London S, Manni JJ, Maugard CM, Morita S, Nazar-Stewart V, Noda K, Oda Y, Parl FF, Pastorelli R, Persson I, Peters WH, Rannug A, Rebbeck T, Risch A, Roelandt L, Romkes M, Ryberg D, Salagovic J, Schoket B, Seidegard J, Shields PG, Sim E, Sinnet D, Strange RC, Stucker I, Sugimura H, To-Figueras J, Vineis P, Yu MC, Taioli E (2001) Metabolic gene polymorphism frequencies in control populations. Cancer Epidemiol Biomarkers Prev 10(12):1239\u20131248","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"Suppl 11","key":"2015_CR28","first-page":"125","volume":"66","author":"J Seidegard","year":"1988","unstructured":"Seidegard J, Pero RW (1988) The genetic variation and the expression of human glutathione transferase mu. Klin Wochenschr 66(Suppl 11):125\u2013126","journal-title":"Klin Wochenschr"},{"issue":"19","key":"2015_CR29","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1073\/pnas.85.19.7293","volume":"85","author":"J Seidegard","year":"1988","unstructured":"Seidegard J, Vorachek WR, Pero RW, Pearson WR (1988) Hereditary differences in the expression of the human glutathione transferase active on trans-stilbene oxide are due to a gene deletion. Proc Natl Acad Sci U S A 85(19):7293\u20137297","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"2015_CR30","doi-asserted-by":"crossref","first-page":"3517","DOI":"10.1074\/jbc.273.6.3517","volume":"273","author":"S Xu","year":"1998","unstructured":"Xu S, Wang Y, Roe B, Pearson WR (1998) Characterization of the human class Mu glutathione S-transferase gene cluster and the GSTM1 deletion. J Biol Chem 273(6):3517\u20133527","journal-title":"J Biol Chem"},{"issue":"2","key":"2015_CR31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0304-3835(96)04832-X","volume":"107","author":"SZ Abdel-Rahman","year":"1996","unstructured":"Abdel-Rahman SZ, el-Zein RA, Anwar WA, Au WW (1996) A multiplex PCR procedure for polymorphic analysis of GSTM1 and GSTT1 genes in population studies. Cancer Lett 107(2):229\u2013233","journal-title":"Cancer Lett"},{"key":"2015_CR32","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1146\/annurev.med.56.082103.104724","volume":"57","author":"M Eichelbaum","year":"2006","unstructured":"Eichelbaum M, Ingelman-Sundberg M, Evans WE (2006) Pharmacogenomics and individualized drug therapy. Annu Rev Med 57:119\u2013137. doi: 10.1146\/annurev.med.56.082103.104724","journal-title":"Annu Rev Med"},{"issue":"Pt 1","key":"2015_CR33","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1042\/bj3000271","volume":"300","author":"S Pemble","year":"1994","unstructured":"Pemble S, Schroeder KR, Spencer SR, Meyer DJ, Hallier E, Bolt HM, Ketterer B, Taylor JB (1994) Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism. Biochem J 300(Pt 1):271\u2013276","journal-title":"Biochem J"},{"issue":"2","key":"2015_CR34","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ejca.2006.09.011","volume":"43","author":"CM Nagle","year":"2007","unstructured":"Nagle CM, Chenevix-Trench G, Spurdle AB, Webb PM (2007) The role of glutathione-S-transferase polymorphisms in ovarian cancer survival. Eur J Cancer 43(2):283\u2013290. doi: 10.1016\/j.ejca.2006.09.011","journal-title":"Eur J Cancer"},{"issue":"8","key":"2015_CR35","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s00432-006-0099-3","volume":"132","author":"EC Morari","year":"2006","unstructured":"Morari EC, Lima AB, Bufalo NE, Leite JL, Granja F, Ward LS (2006) Role of glutathione-S-transferase and codon 72 of P53 genotypes in epithelial ovarian cancer patients. J Cancer Res Clin Oncol 132(8):521\u2013528. doi: 10.1007\/s00432-006-0099-3","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"2015_CR36","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ygyno.2009.01.002","volume":"113","author":"HS Kim","year":"2009","unstructured":"Kim HS, Kim MK, Chung HH, Kim JW, Park NH, Song YS, Kang SB (2009) Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study. Gynecol Oncol 113(2):264\u2013269. doi: 10.1016\/j.ygyno.2009.01.002","journal-title":"Gynecol Oncol"},{"issue":"2","key":"2015_CR37","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2217\/pgs.11.140","volume":"13","author":"A Khrunin","year":"2012","unstructured":"Khrunin A, Ivanova F, Moisseev A, Khokhrin D, Sleptsova Y, Gorbunova V, Limborska S (2012) Pharmacogenomics of cisplatin-based chemotherapy in ovarian cancer patients of different ethnic origins. Pharmacogenomics 13(2):171\u2013178. doi: 10.2217\/pgs.11.140","journal-title":"Pharmacogenomics"},{"issue":"1","key":"2015_CR38","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/tpj.2009.45","volume":"10","author":"AV Khrunin","year":"2010","unstructured":"Khrunin AV, Moisseev A, Gorbunova V, Limborska S (2010) Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patients. Pharmacogenomics J 10(1):54\u201361. doi: 10.1038\/tpj.2009.45","journal-title":"Pharmacogenomics J"},{"issue":"2","key":"2015_CR39","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00008571-199604000-00005","volume":"6","author":"CL Chen","year":"1996","unstructured":"Chen CL, Liu Q, Relling MV (1996) Simultaneous characterization of glutathione S-transferase M1 and T1 polymorphisms by polymerase chain reaction in American whites and blacks. Pharmacogenetics 6(2):187\u2013191","journal-title":"Pharmacogenetics"},{"issue":"4","key":"2015_CR40","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","volume":"15","author":"FE Harrell Jr","year":"1996","unstructured":"Harrell FE Jr, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15(4):361\u2013387. doi: 10.1002\/(SICI)1097-0258(19960229)15:4<361::AID-SIM168>3.0.CO;2-4","journal-title":"Stat Med"},{"issue":"5","key":"2015_CR41","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1007\/s13277-013-1531-3","volume":"35","author":"AL Teixeira","year":"2014","unstructured":"Teixeira AL, Ferreira M, Silva J, Gomes M, Dias F, Santos JI, Mauricio J, Lobo F, Medeiros R (2014) Higher circulating expression levels of miR-221 associated with poor overall survival in renal cell carcinoma patients. Tumour Biol 35(5):4057\u20134066. doi: 10.1007\/s13277-013-1531-3","journal-title":"Tumour Biol"},{"issue":"8","key":"2015_CR42","doi-asserted-by":"crossref","first-page":"e72419","DOI":"10.1371\/journal.pone.0072419","volume":"8","author":"AL Teixeira","year":"2013","unstructured":"Teixeira AL, Gomes M, Nogueira A, Azevedo AS, Assis J, Dias F, Santos JI, Lobo F, Morais A, Mauricio J, Medeiros R (2013) Improvement of a predictive model of castration-resistant prostate cancer: functional genetic variants in TGFbeta1 signaling pathway modulation. PLoS One 8(8):e72419. doi: 10.1371\/journal.pone.0072419","journal-title":"PLoS One"},{"issue":"13","key":"2015_CR43","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","volume":"32","author":"E Pujade-Lauraine","year":"2014","unstructured":"Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P, Bamias A, Pereira D, Wimberger P, Oaknin A, Mirza MR, Follana P, Bollag D, Ray-Coquard I (2014) Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 32(13):1302\u20131308. doi: 10.1200\/JCO.2013.51.4489","journal-title":"J Clin Oncol"},{"issue":"3","key":"2015_CR44","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1002\/cncr.28406","volume":"120","author":"WP Tew","year":"2014","unstructured":"Tew WP, Colombo N, Ray-Coquard I, Del Campo JM, Oza A, Pereira D, Mammoliti S, Matei D, Scambia G, Tonkin K, Shun Z, Sternas L, Spriggs DR (2014) Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study. Cancer 120(3):335\u2013343. doi: 10.1002\/cncr.28406","journal-title":"Cancer"},{"issue":"3","key":"2015_CR45","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2174\/1568009614666140310120107","volume":"14","author":"Z Penzvalto","year":"2014","unstructured":"Penzvalto Z, Surowiak P, Gyorffy B (2014) Biomarkers for systemic therapy in ovarian cancer. Curr Cancer Drug Targets 14(3):259\u2013273","journal-title":"Curr Cancer Drug Targets"},{"issue":"47","key":"2015_CR46","doi-asserted-by":"crossref","first-page":"7265","DOI":"10.1038\/sj.onc.1206933","volume":"22","author":"ZH Siddik","year":"2003","unstructured":"Siddik ZH (2003) Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22(47):7265\u20137279. doi: 10.1038\/sj.onc.1206933","journal-title":"Oncogene"},{"issue":"8","key":"2015_CR47","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/nrc2167","volume":"7","author":"L Kelland","year":"2007","unstructured":"Kelland L (2007) The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer 7(8):573\u2013584. doi: 10.1038\/nrc2167","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"2015_CR48","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ygyno.2008.09.034","volume":"112","author":"F Muggia","year":"2009","unstructured":"Muggia F (2009) Platinum compounds 30\u00a0years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol Oncol 112(1):275\u2013281. doi: 10.1016\/j.ygyno.2008.09.034","journal-title":"Gynecol Oncol"},{"issue":"4","key":"2015_CR49","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nrclinonc.2010.37","volume":"7","author":"T Hogberg","year":"2010","unstructured":"Hogberg T (2010) Chemotherapy: current drugs still have potential in advanced ovarian cancer. Nat Rev Clin Oncol 7(4):191\u2013193. doi: 10.1038\/nrclinonc.2010.37","journal-title":"Nat Rev Clin Oncol"},{"issue":"4","key":"2015_CR50","doi-asserted-by":"crossref","first-page":"402","DOI":"10.2174\/156800912800190875","volume":"12","author":"JJ Marin","year":"2012","unstructured":"Marin JJ, Briz O, Monte MJ, Blazquez AG, Macias RI (2012) Genetic variants in genes involved in mechanisms of chemoresistance to anticancer drugs. Curr Cancer Drug Targets 12(4):402\u2013438","journal-title":"Curr Cancer Drug Targets"},{"issue":"7","key":"2015_CR51","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1634\/theoncologist.2010-0260","volume":"16","author":"MJ Deenen","year":"2011","unstructured":"Deenen MJ, Cats A, Beijnen JH, Schellens JH (2011) Part 3: pharmacogenetic variability in phase II anticancer drug metabolism. Oncologist 16(7):992\u20131005. doi: 10.1634\/theoncologist.2010-0260","journal-title":"Oncologist"},{"issue":"3","key":"2015_CR52","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00428-013-1509-y","volume":"464","author":"X Matias-Guiu","year":"2014","unstructured":"Matias-Guiu X, Davidson B (2014) Prognostic biomarkers in endometrial and ovarian carcinoma. Virchows Arch 464(3):315\u2013331. doi: 10.1007\/s00428-013-1509-y","journal-title":"Virchows Arch"},{"issue":"5","key":"2015_CR53","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1200\/JCO.20.5.1248","volume":"20","author":"RE Bristow","year":"2002","unstructured":"Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002) Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 20(5):1248\u20131259","journal-title":"J Clin Oncol"},{"key":"2015_CR54","doi-asserted-by":"crossref","unstructured":"Yan L, Beckman R (2005) Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development. Biotechniques 39(10 Suppl):S565\u2013S568. doi: 10.2144\/000112043","DOI":"10.2144\/000112043"},{"key":"2015_CR55","doi-asserted-by":"crossref","unstructured":"Shahzad MM, Lopez-Berestein G, Sood AK (2009) Novel strategies for reversing platinum resistance. Drug Resist Updat 12(6):148\u2013152. doi: 10.1016\/j.drup.2009.09.001","DOI":"10.1016\/j.drup.2009.09.001"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2015-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00228-016-2015-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-016-2015-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,24]],"date-time":"2019-05-24T08:49:16Z","timestamp":1558687756000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00228-016-2015-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1,23]]},"references-count":55,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["2015"],"URL":"https:\/\/doi.org\/10.1007\/s00228-016-2015-3","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"type":"print","value":"0031-6970"},{"type":"electronic","value":"1432-1041"}],"subject":[],"published":{"date-parts":[[2016,1,23]]}}}